Drug Approval | September 04, 2021
Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Subscribe To Our Newsletter & Stay Updated
